FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Klaria Pharma Holding AB FCF Yield % Related Terms
Klaria Pharma Holding AB FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klaria Pharma Holding AB FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Klaria Pharma Holding AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Klaria Pharma Holding AB (FRA:6FN) has a FCF Yield % of -18.78 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Klaria Pharma Holding AB and its competitors. According to the industry distribution chart, Klaria Pharma Holding AB ranks #887 out of 1001 companies in the Drug Manufacturers industry, placing it in the top 88.6%.
Is Klaria Pharma Holding AB's FCF Yield % too high?
Klaria Pharma Holding AB's current FCF Yield % is -18.78. Based on the distribution chart, Klaria Pharma Holding AB ranks #887 out of 1001 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Klaria Pharma Holding AB has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Klaria Pharma Holding AB ranks #887 out of 1001 companies for FCF Yield %. This places Klaria Pharma Holding AB in the lower half of its industry. The industry median FCF Yield % is 0.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.65, based on 1,001 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Klaria Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klaria Pharma Holding AB's current FCF Yield % is -18.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.06 — trading 99.3% above its estimated fair value. The current FCF Yield % is -18.78. Klaria Pharma Holding AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current FCF Yield % is -18.78 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?
Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued.
The current stock price of €0.06 is trading 99.3% above its estimated GF Value™ of €0.03.
GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.
Key valuation signals for FRA:6FN:
FCF Yield %: -18.78
GF Value™: €0.03 vs. price of €0.06 (99.3% above fair value)
No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
28GF Score
Get the complete analysis for FRA:6FN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FN has been successfully added to your 
